news
Who Actually Benefits from Classifying Obesity as a Disease?
Max Moser posits that framing obesity as a disease primarily benefits GLP-1 drug makers, drawing parallels to the antidepressant boom. This opinion piece questions the motivations behind the medicalization of obesity, suggesting financial incentives from pharmaceutical companies like Eli Lilly and Novo Nordisk. It asks whether this classification genuinely serves public health or primarily boosts drug sales.
Max Moser posits that framing obesity as a disease primarily benefits GLP-1 drug makers, drawing parallels to the antidepressant boom. This opinion piece questions the motivations behind the medicalization of obesity, suggesting financial incentives from pharmaceutical companies like Eli Lilly and Novo Nordisk. It asks whether this classification genuinely serves public health or primarily boosts drug sales.
The architecture take
The medical establishment's recent embrace of obesity as a 'disease' isn't just about public health; it's a gold rush. Moser nails it: this framing—just like with antidepressants in the 90s—paves the way for pharma to roll out blockbuster drugs like GLP-1s. When you redefine a common metabolic state as a chronic illness requiring lifelong medication, you're not just offering solutions; you're building an entirely new consumer base. What's the real impact on the body? Sure, these drugs can shift glucose metabolism and aid weight loss. But the deeper question is whether a pill-for-every-ill model truly addresses the underlying drivers of metabolic health—like stress, sleep, and lifestyle—or simply treats the symptom while creating dependency. Watch for the public discourse to pivot: from 'lifestyle choice' to 'medical necessity,' and ultimately, to 'insurance-covered prescription.' The industry is banking on it.